Additional file 4 of Timing of kidney biopsy in type 2 diabetic patients: a stepwise approach

Additional file 4:Figure S4. Patient distribution according to diabetic retinopathy, proliferative diabetic retinopathy, DM duration (≥ 5 or  6 /HPF), and diagnosis of kidney pathology. The prevalence of the non-diabetic renal disease in each subgroup is presented at the bottom. PDR, proliferative diabetic retinopathy; NPDR, non-proliferative diabetic retinopathy; DN, diabetic nephropathy; NDRD, non-diabetic renal disease

Additional file 3 of Timing of kidney biopsy in type 2 diabetic patients: a stepwise approach

Additional file 3:Figure S3. The receiver operating characteristic (ROC) curve of duration of diabetes predicting NDRD in patients without diabetic retinopathy. The ROC area under the curve (AUC) = 0.745

Additional file 1 of Timing of kidney biopsy in type 2 diabetic patients: a stepwise approach

Additional file 1:Figure S1. The receiver operating characteristic (ROC) curve of urinary RBC predicting NDRD in patients with diabetic retinopathy. The ROC area under the curve (AUC) = 0.743

Additional file 5 of Timing of kidney biopsy in type 2 diabetic patients: a stepwise approach

Additional file 5:Table S1. Clinical and biochemical characteristics of patients with proliferative diabetic retinopathy. Table S2. Clinical and biochemical characteristics of patients with non-proliferative diabetic retinopathy. Table S3. Clinical and biochemical characteristics of patients without diabetic retinopathy & with DM duration ≥5 years. Table S4. Clinical and biochemical characteristics of patients without diabetic retinopathy & with DM duration < 5 years Table S5. Urinary red blood cells in different pathological diagnosis

Additional file 2 of Timing of kidney biopsy in type 2 diabetic patients: a stepwise approach

Additional file 2:Figure S2. The receiver operating characteristic (ROC) curve of urinary RBC predicting NDRD in patients without diabetic retinopathy. The ROC area under the curve (AUC) = 0.786

Cox proportional hazard model for prognosis of HD patients at a four-year follow-up.

a<p>Values are expressed as mean ± SD or percent.</p>b<p>ACE, angiotensin converting enzyme; ARB, angiotensin receptor blocker.</p>c<p>CI, confidence interval.</p>d<p>HR, hazard ratio.</p>*<p><i>p</i><0.10 in univariate Cox regression analysis.</p

Box plots of plasma vitamin D binding protein and clusterin levels in HD patients.

<p>ELISA validation of vitamin D binding protein and clusterin concentration for patients’ plasma originally analyzed by 2-DE. Long-term HD survivors have (a) higher vitamin D binding protein (204.5±63.9 mg/L vs. 149.0±71.6 mg/L, p = 0.036) and (b) lower clusterin (282.3±105.8 mg/L vs. 438.5±174.2 mg/L, p = 0.011) than the short-term HD patients, which are concordant with 2-DE expression pattern.</p

Kaplan-Meier analysis of plasma DBP level in HD patients.

<p>HD patients with the lowest plasma vitamin D binding protein level were at the highest risk for mortality than those with the top tertile plasma levels (p = 0.03; log-rank test).</p

Representative gel sections of protein alterations related to HD duration.

<p>Each bar represents the intensity of the squared spot quantitatively analyzed by PDQuest software. Circles were used to indicate the α1-antitrypsin and fibrinogen γ chain respectively in (h) and (i) according to SWISS-2DPAGE (<a href="http://tw.expasy.org/ch2d/" target="_blank">http://tw.expasy.org/ch2d/</a>).</p

Demographics and biochemistry of the studied HD population.

<p>Demographics and biochemistry of the studied HD population.</p